Conclusions
HER2-negative, HR-positive, non-visceral disease
Overall, while xentuzumab could be safely combined with everolimus and exemestane, the addition of xentuzumab did not improve PFS in patients with HR-positive, HER2-negative advanced breast cancer with non-visceral disease.